Search

Author/Creator Wäsch, R.

1. A patient with refractory high-grade B-cell lymphoma and rapid progression under CAR-T-cell therapy was successfully salvaged with inotuzumab- ozogamicin. Issue 9 (29th July 2022)

Authors:
Strüßmann, T.; Wäsch, R.; Scherer, F.; Mutter, J. A.; Pfeifer, D.; Bartsch, I.; Giesler, S.; Graziani, G.; Duyster, J.; Finke, J.; Marks, R.
Journal:
Leukemia & lymphoma
Issue:
Volume 63:Issue 9(2022)
Page Start:
2260
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. Prevention, monitoring and treatment of cardiovascular adverse events in myeloma patients receiving carfilzomib A consensus paper by the European Myeloma Network and the Italian Society of Arterial Hypertension. (8th April 2019)

Authors:
Bringhen, S.; Milan, A.; D'Agostino, M.; Ferri, C.; Wäsch, R.; Gay, F.; Larocca, A.; Offidani, M.; Zweegman, S.; Terpos, E.; Goldschmidt, H.; Cavo, M.; Ludwig, H.; Driessen, C.; Auner, H. W.; Caers, J.; Gramatzki, M.; Dimopoulos, M. A.; Boccadoro, M.; Einsele, H.
Journal:
Journal of internal medicine
Issue:
Volume 286:Number 1(2019)
Page Start:
63
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

3. S125: 10-DAY DECITABINE VS. CONVENTIONAL CHEMOTHERAPY ("3 + 7") FOLLOWED BY ALLOGRAFTING (HSCT) IN AML PATIENTS ≥60 YEARS: A RANDOMIZED PHASE III STUDY OF THE EORTC LEUKEMIA GROUP, GIMEMA, CELG, AND GMDS-SG. (23rd June 2022)

Authors:
Lübbert, M.; Wijermans, P.; Kicinski, M.; Chantepie, S.; van der Velden, W.; Noppeney, R.; Griskevicius, L.; Neubauer, A.; Crysandt, M.; Vrhovac, R.; Luppi, M.; Fuhrmann, S.; Audisio, E.; Candoni, A.; Legrand, O.; Foà, R.; Gaidano, G.; van Lammeren-Venema, D.; Posthuma, E. F.; Hoogendoorn, M.
Journal:
HemaSphere
Issue:
Volume 6(2022)Supplement 3
Page Start:
26
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

4. S183: NOVEL COMBINATION IMMUNOTHERAPY FOR THE TREATMENT OF RELAPSED/REFRACTORY MULTIPLE MYELOMA: UPDATED PHASE 1B RESULTS FOR TALQUETAMAB (A GPRC5D X CD3 BISPECIFIC ANTIBODY) IN COMBINATION WITH DARATUMUMAB. (23rd June 2022)

Authors:
van de Donk, N. W.; Bahlis, N.; Mateos, M.-V.; Weisel, K.; Dholaria, B.; Garfall, A. L.; Goldschmidt, H.; Martin, T. G.; Morillo, D.; Reece, D. E.; Hurd, D.; Rodríguez-Otero, P.; Bhutani, M.; D'Souza, A.; Oriol, A.; Askari, E.; San-Miguel, J. F.; Kortüm, K. M.; Vishwamitra, D.; Xin Wang Lin, S.
Journal:
HemaSphere
Issue:
Volume 6(2022)Supplement 3
Page Start:
84
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

5. S188: TECLISTAMAB IN COMBINATION WITH DARATUMUMAB, A NOVEL, IMMUNOTHERAPY-BASED APPROACH FOR THE TREATMENT OF RELAPSED/REFRACTORY MULTIPLE MYELOMA: UPDATED PHASE 1B RESULTS. (23rd June 2022)

Authors:
Rodriguez Otero, P.; D'Souza, A.; Reece, D.; van de Donk, N. W.; Chari, A.; Krishnan, A.; Martin, T.; Mateos, M. V.; Morillo, D.; Hurd, D.; Rosinol, L.; Balari, A. S.; Wäsch, R.; Vishwamitra, D.; Wang Lin, S. X.; Prior, T.; Vandenberk, L.; Smit, M.-A. D.; Oriol, A.; Dholaria, B.
Journal:
HemaSphere
Issue:
Volume 6(2022)Supplement 3
Page Start:
89
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗